Severe parkinsonism associated with anti-CRMP5 antibody-positive paraneoplastic neurological syndrome and abnormal signal intensity in the bilateral basal ganglia

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 87, Issue 8, 2016, Pages 907-910

  Tada, Satoru ^a,b   Furuta, Mitsuru ^c   Fukada, Kei ^b   Hirozawa, Daisuke ^d   Matsui, Misa ^e   Aoike, Futoshi ^f   Okuno, Tatsusada ^c   Sawada, Jin Ichi ^b   Mochizuki, Hideki ^c   Hazama, Takanori ^b  

^a INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^b OSAKA GENERAL MEDICAL CENTER   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION   (Japan)

^e TONEYAMA NATIONAL HOSPITAL   (Japan)

^f Department of Urology Tane General Hospital   (Japan)

Author keywords

MOVEMENT DISORDERS; NEUROIMMUNOLOGY; NEUROONCOLOGY; PARANEOPLASTIC SYNDROME; Parkinson'S DISEASE

Indexed keywords

CARBOPLATIN; CRMP5 ANTIBODY; DOPA; ETOPOSIDE; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

AGED; BASAL GANGLION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CONSTIPATION; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DYSARTHRIA; FOLLOW UP; GAIT DISORDER; HUMAN; HYPERSALIVATION; LABORATORY TEST; LETTER; LYMPH NODE BIOPSY; MALE; NEUROIMAGING; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PARANEOPLASTIC NEUROPATHY; PARKINSONISM; PRIORITY JOURNAL; SMALL CELL LUNG CANCER; WALKING DIFFICULTY; ABNORMALITIES; BRAIN; CHRONIC LYMPHATIC LEUKEMIA; DIAGNOSTIC IMAGING; PATHOLOGY;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BASAL GANGLIA; BRAIN; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM; PARKINSONIAN DISORDERS;

EID: 84941710444     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2015-311569     Document Type: Letter

References (10)

1. Yu Z, Kryzer TJ, Griesmann GE, et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001;49:146-54.
2. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004;75:1135-40.
3. Golbe LI, Miller DC, Duvoisin RC. Paraneoplastic degeneration of the substantia nigra with dystonia and parkinsonism. Mov Disord 1989;4:147-52.
4. Pittock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol 2003;53:580-7.
5. Tan KM, Lennon VA, Klein CJ, et al. Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology 2008;70:1883-90.
6. Vigliani MC, Honnorat J, Antoine JC, et al. Chorea and related movement disorders of paraneoplastic origin: the PNS EuroNetwork experience. J Neurol 2011;258:2058-68.
7. Bretin S, Reibel S, Charrier E, et al. Differential expression of CRMP1, CRMP2A, CRMP2B, and CRMP5 in axons or dendrites of distinct neurons in the mouse brain. J Comp Neurol 2005;486:1-17.
8. Honnorat J, Antoine JC. Paraneoplastic neurological syndromes. Orphanet J Rare Dis 2007;2:22.
9. Rosenfeld MR, Dalmau J. Diagnosis and management of paraneoplastic neurologic disorders. Curr Treat Options Oncol 2013;14:528-38.
10. Honnorat J. Early-onset immunotherapy by intravenous immunoglobulin and corticosteroids in well characterized onconeural-antibody-positive paraneoplastic neurological syndrome. Clin Exp Immunol 2014;178(Suppl 1):127-9.